PF-06939926

GENETIC3 trials

Sponsors

Pfizer

Conditions

Duchenne Muscular DystrophyMuscular Dystrophy, Duchenne

Phase 1

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

TerminatedNCT03362502

PfizerDuchenne Muscular Dystrophy

Start: 2018-01-23End: 2025-07-28Updated: 2025-09-15

Phase 2

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

TerminatedNCT05429372

PfizerMuscular Dystrophy, Duchenne

Start: 2022-08-08End: 2025-10-03Updated: 2025-10-21

Phase 3

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Active, not recruitingNCT04281485

PfizerDuchenne Muscular Dystrophy

Start: 2020-11-05End: 2039-04-15Updated: 2026-07-22

Related Papers

Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.

2026-03-01

Dystrophin/mini-dystrophin expression analysis by immunoaffinity liquid chromatography-tandem mass spectrometry after gene therapy for DMD.

2025-08-02

Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial.

2025-06-283 citations

Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy.

2025-06-282 citations

AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial.

2025-06-273 citations

Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy

Scientific Reports2025-01-0216 citations

Monitoring Activity and Gait in Children (MAGIC) using digital health technologies.

2024-03-212 citations

Non-invasive gene delivery across the blood-brain barrier: present and future perspectives

Neural Regeneration Research2021-08-2910 citations